13F reference period
Q2 2026
Security Snapshot
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) Institutional Ownership
CUSIP: 74065P101
13F Institutional Holders and Ownership History from Q3 2020 to Q3 2026
Institutions Reporting
75
Shares (Excl. Options)
49.6M
Full value: 49,599,406 · shares · 30 Jun 2026Price
$5.33
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PRLD on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 49,599,406
- Total 13F value
- $264,336,295
- Portfolio coverage rank
- 0%
- Share change
- +18,835,301
- Value change
- +$103,545,263
- Number of holders
- 75
- Shares outstanding
- 64,968,808
- SEC-reported price per share
- $3.88
- Insider filing price
- $3.88
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share is tracked under CUSIP 74065P101.
- 75 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 55 to 75 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$105.24M
Full value: $105,239,465 · USD · 31 Mar 2026.$264.34M
Full value: $264,336,295 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 75 institutions filings for Q2 2026.
Security key
74065P101
13F reference period
Q2 2026
13F holders
75
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
PRLD full holder history
Prelude Therapeutics Inc SEC filings
Prelude Therapeutics Inc company facts
Prelude Therapeutics Inc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74065P101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
PRLD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 16% | $44,259,932 | 12,935,071 | ORBIMED ADVISORS LLC | 21 Apr 2026 | |||
| BAKER BROS. ADVISORS LP | 16% | -33% | $35,227,431 | +$86,682 | 10,295,301 | +0.25% | Baker Bros. Advisors LP | 20 Apr 2026 |
| Vaddi Krishna | 13% | -4.6% | $19,562,376 | +$1,008,643 | 6,745,647 | +5.4% | Vaddi Krishna | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $22,157,579 | 6,477,309 | RA Capital Management, L.P. | 21 Apr 2026 | |||
| INCYTE CORP | 9.9% | $6,295,859 | 4,372,124 | INCYTE CORP | 03 Nov 2025 | |||
| Soleus Private Equity Fund III, L.P. | 5.2% | $13,310,809 | 3,378,378 | Soleus Capital Management, L.P. | 21 Apr 2026 |
As of 30 Jun 2026,
75
institutional investors reported holding
shares of
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD).
This represents
76%
of the company’s total
outstanding shares.
49.6M
Full value: 49,599,406 · shares · 30 Jun 202664.97M
Full value: 64,968,808 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 21% | 13,724,571 | +26% | 1.4% | $73,151,963 |
| BAKER BROS. ADVISORS LP | 16% | 10,123,824 | 0% | 0.27% | $53,959,982 |
| RA CAPITAL MANAGEMENT, L.P. | 10% | 6,475,882 | 0.3% | $34,516,451 | |
| Soleus Capital Management, L.P. | 5.2% | 3,378,378 | 0.62% | $18,006,755 | |
| Kynam Capital Management, LP | 3.7% | 2,415,087 | +52% | 0.71% | $12,872,414 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 2,009,445 | +63% | 0% | $10,710,342 |
| BlackRock, Inc. | 2.8% | 1,797,501 | +458% | 0% | $9,580,681 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.6% | 1,019,832 | +83% | 0.78% | $5,435,705 |
| TWO SIGMA INVESTMENTS, LP | 1.5% | 993,369 | +7.6% | 0% | $5,294,657 |
| ADAR1 Capital Management, LLC | 1.4% | 900,900 | +489% | 0.23% | $4,801,797 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 844,993 | +121% | 0% | $4,503,813 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 841,862 | +178% | 0% | $4,487,860 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.2% | 766,095 | 0.01% | $4,083,286 | |
| ACADIAN ASSET MANAGEMENT LLC | 0.94% | 611,359 | +20% | 0% | $3,253,000 |
| MORGAN STANLEY | 0.78% | 503,860 | +56% | 0% | $2,685,574 |
| STATE STREET CORP | 0.66% | 428,787 | +210% | 0% | $2,285,435 |
| UBS Group AG | 0.49% | 318,797 | +394% | 0% | $1,699,188 |
| VANGUARD FIDUCIARY TRUST CO | 0.44% | 284,886 | +81% | 0% | $1,518,442 |
| RENAISSANCE TECHNOLOGIES LLC | 0.43% | 281,200 | +2.2% | 0% | $1,498,796 |
| NORTHERN TRUST CORP | 0.37% | 240,599 | +380% | 0% | $1,282,393 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.3% | 193,920 | 0% | $1,033,594 | |
| MARSHALL WACE, LLP | 0.29% | 190,692 | -47% | 0% | $1,016,387 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.19% | 125,606 | +15% | 0% | $669,480 |
| GOLDMAN SACHS GROUP INC | 0.19% | 120,834 | -49% | 0% | $644,045 |
| Hillsdale Investment Management Inc. | 0.13% | 81,400 | 0.01% | $433,862 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Headline period
Q2 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 112,923 | $441,907 | +$274,829 | $3.91 | 9 |
| 2026 Q2 | 49,599,406 | $264,336,295 | +$103,545,263 | $5.33 | 75 |
| 2026 Q1 | 30,772,368 | $105,239,465 | +$8,578,948 | $3.42 | 55 |
| 2025 Q4 | 28,472,272 | $82,563,685 | +$4,105,694 | $2.90 | 48 |
| 2025 Q3 | 27,161,835 | $39,111,943 | +$249,044 | $1.44 | 45 |
| 2025 Q2 | 27,187,955 | $21,995,839 | -$2,401,932 | $0.81 | 49 |
| 2025 Q1 | 30,289,302 | $23,267,043 | -$2,260,767 | $0.77 | 56 |
| 2024 Q4 | 32,136,788 | $40,964,573 | -$12,964,360 | $1.28 | 60 |
| 2024 Q3 | 35,754,682 | $74,021,916 | +$3,111,676 | $2.07 | 69 |
| 2024 Q2 | 33,917,161 | $129,220,239 | -$1,353,555 | $3.81 | 59 |
| 2024 Q1 | 34,197,005 | $162,095,049 | -$2,346,403 | $4.74 | 56 |
| 2023 Q4 | 34,725,223 | $148,268,893 | -$6,317,081 | $4.27 | 55 |
| 2023 Q3 | 36,614,209 | $113,138,241 | +$1,036,814 | $3.09 | 57 |
| 2023 Q2 | 36,273,689 | $163,232,997 | +$31,250,061 | $4.50 | 52 |
| 2023 Q1 | 31,510,272 | $179,609,477 | +$1,734,926 | $5.70 | 54 |
| 2022 Q4 | 31,178,634 | $188,300,136 | -$4,385,760 | $6.04 | 59 |
| 2022 Q3 | 31,821,580 | $210,332,653 | -$5,208,246 | $6.61 | 50 |
| 2022 Q2 | 32,736,159 | $170,877,689 | -$7,216,025 | $5.22 | 55 |
| 2022 Q1 | 34,109,145 | $235,382,986 | -$10,995,652 | $6.90 | 64 |
| 2021 Q4 | 35,151,511 | $437,636,391 | -$26,977,029 | $12.45 | 74 |
| 2021 Q3 | 35,967,344 | $1,123,981,157 | +$47,268,239 | $31.25 | 61 |
| 2021 Q2 | 34,458,535 | $986,644,054 | +$52,903,899 | $28.63 | 56 |
| 2021 Q1 | 32,543,650 | $1,410,113,760 | -$96,898,538 | $43.33 | 60 |
| 2020 Q4 | 34,651,491 | $2,474,382,581 | +$136,089,518 | $71.55 | 51 |
| 2020 Q3 | 33,322,061 | $999,836,330 | +$999,836,330 | $30.13 | 38 |